1,082 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Whipplewood Advisors LLC

Whipplewood Advisors LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 1,082 shares of the company’s stock, valued at approximately $192,000.

A number of other large investors have also bought and sold shares of ABBV. NewEdge Wealth LLC lifted its holdings in AbbVie by 7.6% during the 4th quarter. NewEdge Wealth LLC now owns 203,124 shares of the company’s stock worth $36,095,000 after buying an additional 14,422 shares in the last quarter. Checchi Capital Advisers LLC lifted its holdings in AbbVie by 0.3% during the 4th quarter. Checchi Capital Advisers LLC now owns 23,353 shares of the company’s stock worth $4,150,000 after buying an additional 61 shares in the last quarter. Bryn Mawr Capital Management LLC lifted its holdings in AbbVie by 4.5% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 7,154 shares of the company’s stock worth $1,271,000 after buying an additional 306 shares in the last quarter. Riverpoint Wealth Management Holdings LLC lifted its holdings in AbbVie by 0.9% during the 4th quarter. Riverpoint Wealth Management Holdings LLC now owns 8,256 shares of the company’s stock worth $1,467,000 after buying an additional 75 shares in the last quarter. Finally, National Pension Service lifted its holdings in AbbVie by 1.9% during the 4th quarter. National Pension Service now owns 3,416,539 shares of the company’s stock worth $607,119,000 after buying an additional 65,017 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 5,778 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the completion of the sale, the executive vice president now owns 22,381 shares of the company’s stock, valued at $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of analyst reports. UBS Group increased their price target on AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Guggenheim increased their price target on AbbVie from $212.00 to $214.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Morgan Stanley increased their price target on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Raymond James reissued an “outperform” rating and issued a $220.00 price target (up previously from $218.00) on shares of AbbVie in a research note on Monday, February 3rd. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $220.00 price target on shares of AbbVie in a research note on Tuesday, December 17th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $208.35.

AbbVie Price Performance

ABBV stock opened at $205.06 on Friday. The stock has a 50-day moving average price of $183.75 and a two-hundred day moving average price of $186.85. The stock has a market cap of $362.00 billion, a PE ratio of 85.44, a price-to-earnings-growth ratio of 1.62 and a beta of 0.58. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the prior year, the firm posted $2.79 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Tuesday, April 15th. AbbVie’s payout ratio is 273.33%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.